Journal of Korean Traditional Oncology (대한암한의학회지)

Korean Association of Traditional Oncology (대한암한의학회)
권호 표지
DOI QR코드

DOI QR Code

5-FU or capecitabine based chronomodulated chemotherapy for advanced colorectal cancer: mata-analysis and systematic review

진행성 대장직장암 환자군에 있어서 5-FU 혹은 capecitabine의 최적 시간 치료법에 대한 체계적 고찰 : 메타분석

  • Lee, Jee Young (Dept. Internal medicine, Korean medicine cancer center, Kyung Hee University hospital at Gangdong) ;
  • Oh, Hye Kyung (Dept. Internal medicine, Korean medicine cancer center, Kyung Hee University hospital at Gangdong) ;
  • Ryu, Han Sung (Dept. Internal medicine, Korean medicine cancer center, Kyung Hee University hospital at Gangdong) ;
  • Yoon, Seong Woo (Dept. Internal medicine, Korean medicine cancer center, Kyung Hee University hospital at Gangdong)
  • 이지영 (강동경희대학교병원 한방암센터 한방내과) ;
  • 오혜경 (강동경희대학교병원 한방암센터 한방내과) ;
  • 류한성 (강동경희대학교병원 한방암센터 한방내과) ;
  • 윤성우 (강동경희대학교병원 한방암센터 한방내과)
  • Received : 2015.03.28
  • Accepted : 2015.04.20
  • Published : 2015.04.25
Download PDF
⟨ Previous Next ⟩

Abstract

Background : The purpose of this study is to investigate the efficacy and safety of the circadian delivery schedule of fluorouracil or capecitabine based chemotherapy for advanced colorectal cancer. Patients and methods : A meta-analysis was performed using individual data from eight international randomized clinical trials, especially phase II or III trials, comparing 5-fluorouracil, or capeticabine in chronomodulated or conventional schedule. The data from 8 studies was composed of 692 patients receiving chronomodulated chemotheray and 684 patients receiving conventional chemotherapy. The main end point was response rate. Results : Response rate was insignificantly different from each group (RR 1.14, 95%CI 0.74-1.74, p=0.55). Overall survival and progresseion-free survival were not significant either. Chemotherapy induced anemia, diarrhea, and nausea/vomiting were worse in the chronotherapy group, with statistic significance respectively. On the other hand, chemotherapy induced thrombocytopenia, stomatitis, peripheral neuropathy, and dermatotoxicity were better but they were not statistically significant results. Conclusions : Patients lived longer but not significantly on chronomodulated chemotherapy rather than on conventional chemotherapy. Patients on chronomodulated chemotherapy experienced adverse events more. The chronomodulated chemotherapy schedule needs adjustment of its delivery schedule and further research is required.

Keywords

References

  1. Greene MW, Circadian rhythms and tumor growth, Cancer letters 2012;318:115-23. https://doi.org/10.1016/j.canlet.2012.01.001
  2. Takeda N, Maemura K, Circiadian clock and cardiovascular disease, J Cardiol 2011;57(3):249-56. https://doi.org/10.1016/j.jjcc.2011.02.006
  3. Bonny O, Firsov D, Circadian regulation of renal function and potential role in hypertension, Curr Opin Nephrol Hypertens 2013;22(4):439-44. https://doi.org/10.1097/MNH.0b013e32836213b8
  4. Durrington HJ, Farrow SN, Loudon AS, Ray DW, The circadian clock and asthma, Thorax 2014;69(1):90-2. https://doi.org/10.1136/thoraxjnl-2013-203482
  5. G?mez-Abell?n P, Madrid JA, Ordov?s JM, Garaulet M. Chronobiological aspects of obesity and metabolic syndrome, Endocrinol Nutr 2012;59(1):50-61. https://doi.org/10.1016/j.endonu.2011.08.002
  6. Innominato PF, Levi FA, Bjarnason GA, Chronotherapy and the molecular clock: Clinical implications in oncology, Adv drug deliv rev 2010;62:979-1001. https://doi.org/10.1016/j.addr.2010.06.002
  7. Savvidis C, Koutsilieris M, Circadian rhythm disruption in cancer biology, Mol Med 2012;18:1249-60.
  8. Mormont MC, Levi F, Circadian-system alterations during cancer processes: a review. Int J Cancer 1997;70(2):241-7. https://doi.org/10.1002/(SICI)1097-0215(19970117)70:2<241::AID-IJC16>3.0.CO;2-L
  9. Blask DE, Dauchy RT, Dauchy EM, Mao L, Hill SM, Greene MW, et al. Light exposure at night disrupts host/cancer circadian regulatory dynamics: impact on the Warburg effect, lipid signaling and tumor growth prevention, PLoS One 2014;9(8):e102776. https://doi.org/10.1371/journal.pone.0102776
  10. Zhao H, Yin JY, Yang WS, Qin Q, Li TT, Shi Y, et al. Sleep duration and cancer risk: a systematic review and meta-analysis of prospective studies. Asian Pac J Cancer Prev 2013;14(12):7509-15. https://doi.org/10.7314/APJCP.2013.14.12.7509
  11. Tilma Vistisen H, Helene Garde A, Marie Hansen A, Hansen J, Christiansen P, Kolstad H, 0222 night work and breast cancer risk among women in the public Danish health care sector ? a short-term follow up of a large scale population. Occup Environ Med 2014;71(1):A30. https://doi.org/10.1136/oemed-2013-101597
  12. Papantoniou K, Kogevinas M, Martin Sanchez V, Moreno V, Pollan M, Moleon JJ, 0058 Colorectal cancer risk and shift work in a population-based case-control study in Spain (MCC-Spain). Occup Environ Med 2014;71(1):A5-6.
  13. Eriguchi M, Levi F, Hisa T, Yanagie H, Nonaka Y, Takeda Y, Chronotherapy for cancer, Biomedicine & Pharmaco, 2003;57:92-5. https://doi.org/10.1016/j.biopha.2003.08.012
  14. Levi F, Focan C, Karaboue A, de la Valette V, Focan-Henrard D, Baron B, et al. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics, Adv Drug Deliv Rev 2007;59(9-10):1015-35. https://doi.org/10.1016/j.addr.2006.11.001
  15. 안창범, 이윤호, 자오유주침법에 대한 문헌적 고찰, 대한침구학회지 1986;3:61-82.
  16. 황현서, 김기현, 박동석, 자오유주납갑법에 관한 고찰, 대한침구학회지 1997;14(1):155-64.
  17. Levi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial, J Natl Cancer Inst 1994;86(21):1608-17. https://doi.org/10.1093/jnci/86.21.1608
  18. Levi F, Zidani R, Misset JL, Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer, Lancet 1997;350:681-6. https://doi.org/10.1016/S0140-6736(97)03358-8
  19. Thrall MM, Wood P, King V, Rivera W, Hrushesky W, Investigation of the comparative toxicity of 5-FU bolus versus 5-FU continuous infusion circadian chemotherapy with concurrent radiation therapy in locally advanced rectal cancer, Int J Radiation Oncology Biol Phys 2000;46(4):873-81. https://doi.org/10.1016/S0360-3016(99)00456-3
  20. Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HER, et al. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma, Clin Colorectal Cancer 2004;3(4):235-42. https://doi.org/10.3816/CCC.2004.n.004
  21. Garufi C, Vanni B, Aschelter AM, Zappala AR, Bria E, Nistico C, et al. Randomized phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients, Euro J Cancer 2005;42:608-16.
  22. Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellii M, et al. Phase III trial comparind 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the european organisation for research and treatment of cancer chronotherapy group, J Clin Oncol 2006;24(22):3562-9. https://doi.org/10.1200/JCO.2006.06.1440
  23. Ramanathan RK, Bjarnason GA, Bernard SA, Desimone P, Braich T, Evers JP, et al. A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer, Clin Colorectal Cancer, 2008;7(2):134-9. https://doi.org/10.3816/CCC.2008.n.018
  24. Qvortrup C, Jensen BV, Fokstuen T, Nielsen SE, Keldsen N, Glimelius B, et al. A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX30 and chronomodulated XELOX30 as first-line therapy in patients with advanced colorectal cancer, Ann of Oncol 2010;21:87-91. https://doi.org/10.1093/annonc/mdp272
  25. Liao C, Li J, Bin Q, Cao Y, Gao F, Chronomodulated chemotherapy versus conventional chemotherapy for advanced colorectal cancer: a meta-analysis of five randomized controlled trials, Int J Colorectal Dis 2010;25:343-50. https://doi.org/10.1007/s00384-009-0838-4
  26. Giacchetti S, Dugue PA, Innominato PF, Bjarnason GA, Focan C, Garufi C, et al. Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis, Annals of Oncology 2012;23:3110-6. https://doi.org/10.1093/annonc/mds148
  27. Seki K, Chisaka M, Eriguchi M, Yanagie H, Hisa T, Osada I, et al. An attempt to integrate western and chinese medicine: rationale for applying chinese medicine as chronotherapy against cancer, Biomed Pharmacother 2005;59(1):S132-40. https://doi.org/10.1016/S0753-3322(05)80021-6